|
|
||||||||
Department of Medicine, National University of Ireland, University College Cork and Cork University Hospital, Ireland
Immune perception of intestinal contents reflects a functional dualism with systemic hyporesponsiveness to dietary antigens and resident microflora (oral tolerance) and active immune responses to mucosal pathogens. This facilitates optimal absorption of dietary nutrients while conserving immunologic resources for episodic pathogenic challenge. Discrimination between dangerous and harmless antigens within the enteric lumen requires continual sampling of the microenvironment by multiple potential pathways, innate and adaptive recognition mechanisms, bidirectional lymphoepithelial signaling, and rigorous control of effector responses. Errors in these processes disrupt mucosal homeostasis and are associated with food hypersensitivity and mucosal inflammation. Mechanisms of mucosal immune perception and handling of dietary proteins and other antigens have several practical and theoretical implications including vaccine design, therapy of systemic autoimmunity, and alteration of enteric flora with probiotics.
microflora; dietary antigens; oral tolerance; mucosal immunity; inflammatory bowel diseases; probiotics
This article has been cited by other articles:
![]() |
L. O'Mahony, L. O'Callaghan, J. McCarthy, D. Shilling, P. Scully, S. Sibartie, E. Kavanagh, W. O. Kirwan, H. P. Redmond, J. K. Collins, et al. Differential cytokine response from dendritic cells to commensal and pathogenic bacteria in different lymphoid compartments in humans Am J Physiol Gastrointest Liver Physiol, April 1, 2006; 290(4): G839 - G845. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Revolledo, A. J. P. Ferreira, and G. C. Mead Prospects in Salmonella Control: Competitive Exclusion, Probiotics, and Enhancement of Avian Intestinal Immunity J. Appl. Poult. Res., January 1, 2006; 15(2): 341 - 351. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Shanahan Physiological Basis for Novel Drug Therapies Used to Treat the Inflammatory Bowel Diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease Am J Physiol Gastrointest Liver Physiol, March 1, 2005; 288(3): G417 - G421. [Abstract] [Full Text] [PDF] |
||||
![]() |
F Shanahan Probiotics in inflamatory bowel disease Gut, May 1, 2001; 48(5): 609 - 609. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |